Avelumab + Lenvatinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Central Nervous System Tumors
Conditions
Central Nervous System Tumors
Trial Timeline
Dec 3, 2021 → Sep 30, 2026
NCT ID
NCT05081180About Avelumab + Lenvatinib
Avelumab + Lenvatinib is a phase 1 stage product being developed by Merck for Central Nervous System Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05081180. Target conditions include Central Nervous System Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05081180 | Phase 1 | Active |
Competing Products
20 competing products in Central Nervous System Tumors